Literature DB >> 11584063

In vitro evidence for homologous recombinational repair in resistance to melphalan.

Z M Wang1, Z P Chen, Z Y Xu, G Christodoulopoulos, V Bello, G Mohr, R Aloyz, L C Panasci.   

Abstract

BACKGROUND: The generation of DNA interstrand cross-links is thought to be important in the cytotoxicity of nitrogen mustard alkylating agents, such as melphalan, which have antitumor activity. Cell lines with mutations in recombinational repair pathways are hypersensitive to nitrogen mustards. Thus, resistance to melphalan may require accelerated DNA repair by either recombinational repair mechanisms involving Rad51-related proteins (including x-ray repair cross-complementing proteins Xrcc2, Xrcc3, and Rad52) or by nonhomologous endjoining involving DNA-dependent protein kinase (DNA-PK) and Ku proteins. We investigated the role of DNA repair in melphalan resistance in epithelial tumor cell lines.
METHODS: Melphalan cytotoxicity was determined in 14 epithelial tumor cell lines by use of the sulforhodamine assay. Homologous recombinational repair involving Rad51-related proteins was investigated by determining the levels of Rad51, Rad52, and Xrcc3 proteins and the density of nuclear melphalan-induced Rad51 foci, which represent sites of homologous recombinational repair. Nonhomologous endjoining was investigated by determining the levels of Ku70 and Ku86 proteins and DNA-PK activity. Linear regression analysis was used to analyze correlations between the various protein levels, DNA-PK activity, or Rad51 foci formation and melphalan cytotoxicity. All statistical tests were two-sided.
RESULTS: Melphalan resistance was correlated with Xrcc3 levels (r =.587; P =.027) and the density of melphalan-induced Rad51 foci (r =.848; P =.008). We found no correlation between melphalan resistance and Rad51, Rad52, or Ku protein levels or DNA-PK activity.
CONCLUSION: Correlations of melphalan resistance in epithelial tumor cell lines with Xrcc3 protein levels and melphalan-induced Rad51 foci density suggest that homologous recombinational repair is involved in resistance to this nitrogen mustard.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584063     DOI: 10.1093/jnci/93.19.1473

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  10 in total

1.  A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.

Authors:  David Abasiwani Alagpulinsa; Shmuel Yaccoby; Srinivas Ayyadevara; Robert Joseph Shmookler Reis
Journal:  Cancer Biol Ther       Date:  2015-05-21       Impact factor: 4.742

2.  Polymorphisms of phase II xenobiotic-metabolizing and DNA repair genes and in vitro N-ethyl-N-nitrosourea-induced O6-ethylguanine levels in human lymphocytes.

Authors:  Li Jiao; Ping Chang; Pervez F Firozi; Dejian Lai; James L Abbruzzese; Donghui Li
Journal:  Mutat Res       Date:  2006-12-08       Impact factor: 2.433

3.  The Ku-dependent non-homologous end-joining pathway contributes to low-dose radiation-stimulated cell survival.

Authors:  Xiaoyan Yu; Hongyan Wang; Ping Wang; Benjamin P C Chen; Ya Wang
Journal:  J Cell Physiol       Date:  2011-02       Impact factor: 6.384

4.  Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.

Authors:  Ping Zhou; Julie Teruya-Feldstein; Ping Lu; Martin Fleisher; Adam Olshen; Raymond L Comenzo
Journal:  Blood       Date:  2007-11-02       Impact factor: 22.113

5.  A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.

Authors:  Arghya Ray; Durgadevi Ravillah; Deepika S Das; Yan Song; Eva Nordström; Joachim Gullbo; Paul G Richardson; Dharminder Chauhan; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2016-04-20       Impact factor: 6.998

6.  A role for XRCC2 gene polymorphisms in breast cancer risk and survival.

Authors:  Wei-Yu Lin; Nicola J Camp; Lisa A Cannon-Albright; Kristina Allen-Brady; Sabapathy Balasubramanian; Malcolm W R Reed; John L Hopper; Carmel Apicella; Graham G Giles; Melissa C Southey; Roger L Milne; Jose I Arias-Pérez; Primitiva Menéndez-Rodríguez; Javier Benítez; Magdalena Grundmann; Natalia Dubrowinskaja; Tjoung-Won Park-Simon; Thilo Dörk; Montserrat Garcia-Closas; Jonine Figueroa; Mark Sherman; Jolanta Lissowska; Douglas F Easton; Alison M Dunning; Preetha Rajaraman; Alice J Sigurdson; Michele M Doody; Martha S Linet; Paul D Pharoah; Marjanka K Schmidt; Angela Cox
Journal:  J Med Genet       Date:  2011-05-31       Impact factor: 6.318

7.  The effect of a DNA repair gene on cellular invasiveness: XRCC3 over-expression in breast cancer cells.

Authors:  Veronica L Martinez-Marignac; Amélie Rodrigue; David Davidson; Martin Couillard; Ala-Eddin Al-Moustafa; Mark Abramovitz; William D Foulkes; Jean-Yves Masson; Raquel Aloyz
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

8.  Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms.

Authors:  Ching-Ying Kuo; Wen-Cheng Chou; Chin-Chung Wu; Teng-Song Wong; Rajesh Kakadiya; Te-Chang Lee; Tsann-Long Su; Hui-Chun Wang
Journal:  Oncotarget       Date:  2015-09-22

Review 9.  Mechanisms of Drug Resistance in Veterinary Oncology- A Review with an Emphasis on Canine Lymphoma.

Authors:  Maurice Zandvliet; Erik Teske
Journal:  Vet Sci       Date:  2015-08-12

10.  XRCC3 and RAD51 expression are associated with clinical factors in breast cancer.

Authors:  Jia Hu; Ning Wang; Ya-Jie Wang
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.